Unicure Remedies

What Unicure Remedies does

Unicure Remedies Pvt. Ltd. is an Indian pharmaceutical manufacturer headquartered in Vadodara, Gujarat, founded in 1979/1980 and operating as a privately held company. The company specializes in the production of general tablets, hormonal tablets (including contraception and hormone replacement therapy formulations), and oral powders (including oral rehydration salts) for export to global markets. It operates WHO GMP-approved manufacturing facilities with ISO 9001:2015 and ISO 14489:2018 certifications, and holds country-specific regulatory accreditations in Kenya, Peru, Malawi, Zambia, Tanzania, Lesotho, and Yemen, supporting market access across Africa, Latin America, the Middle East, Southeast Asia, and the Caribbean. The company claims over 400 products registered globally and has developed in-house branded products RECHARGE and RECHARGE PLUS for oral rehydration therapy.

The company's business model is B2B contract manufacturing and export, serving international pharmaceutical distributors, brand owners, and healthcare companies seeking manufacturing capabilities for generic pharmaceutical products. Revenue is generated through one-time product sales via negotiated B2B contracts priced by volume, formulation requirements, and destination market. The company provides end-to-end services including product registration support, custom formulation, packaging, and logistics coordination. Its in-house R&D capabilities support both custom client formulations and proprietary branded products, though no AI/ML or digital technology capabilities are evident. The company is founder/management-owned with no disclosed external investment, is led by Mr. V. P. Divanji (Chairman & MD), Mr. N. R. Chinoy (Executive Director - Marketing, 38 years' experience), and Mrs. Shyla Murthy (General Manager - Quality and Regulatory Affairs, 21 years' experience).

Name

Unicure Remedies

Legal name

Unicure Remedies Pvt. Ltd.

Website

https://unicurepharma.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

101–250 employees

Short description

Unicure Remedies is an Indian WHO GMP-certified pharmaceutical manufacturer in Vadodara specializing in general tablets, hormonal tablets, and oral powders, exporting 400+ registered products to distributors and brand owners across Africa, Latin America, Southeast Asia, and the Caribbean.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical manufacturing
• Generic drug production
• Oral rehydration therapy
• Hormonal tablet formulations
• Contract manufacturing services

Headquarters

HQ city

Vadodara

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Manufacturing & Export: Contract manufacturing of generic pharmaceutical products including general tablets, hormonal tablets, and oral powders for international markets. Revenue generated through product sales to global pharmaceutical distributors and brand owners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Unicure Remedies is a pharmaceutical manufacturing company that produces and exports general tablets, oral powders, and hormonal tablets across multiple therapeutic categories. The company manufactures its own branded products (including the RECHARGE oral glucose therapy line developed through in-house R&D) and also offers contract manufacturing services for international pharmaceutical distributors, brand owners, and healthcare companies operating in Africa, Latin America, South East Asia, and the Caribbean.

Product overview

Unicure Remedies is a pharmaceutical manufacturing company specializing in three core product lines: General Tablets, Oral Powders, and Hormonal Tablets. The General Tablets portfolio spans over 15 therapeutic categories including cardiovascular, anti-diabetic, anti-malarial, pain management, antibiotics, anti-fungal, anti-viral, CNS, urology, antiallergens, and supplements. The Oral Powders line includes Oral Rehydration Salts (ORS) formulations (RECHARGE and RECHARGE PLUS flagship brands), N-acetyl-L-cysteine powders, and mineral supplements. The Hormonal Tablets division focuses on contraception products and Hormone Replacement Therapy (HRT). All products are exported across African, Latin American, South East Asian, and Caribbean markets with over 400 products registered globally.

Differentiator

Problem solved

Functional benefit

Brands

• RECHARGE: Flagship oral glucose therapy brand developed through in-house R&D efforts for Oral Rehydration Therapy.
• RECHARGE PLUS

Products and services

• General Tablets

Quantifiable outcome

• 400+ products registered across global markets
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves5 records

Expansion highlights8 records

Broad incumbents

• Glenmark Pharmaceuticals: Indian-headquartered pharmaceutical company with manufacturing operations and presence across emerging and developed markets including Africa, Asia, and Latin America. Comparable for its India-based generic manufacturing model and overseas market focus.
• Lupin: Indian generic pharmaceutical manufacturer with significant presence in emerging markets including Africa and Latin America, plus developed markets. Comparable as an Indian generic exporter with broad therapeutic coverage and WHO GMP-certified manufacturing facilities.
• Zydus Lifesciences (Cadila Healthcare): Indian pharmaceutical group with manufacturing across formulations, APIs, and biosimilars and a global footprint. Comparable as a large Indian pharma manufacturer with WHO GMP facilities and exports to multiple emerging and developed markets.
• Alkem Laboratories: Indian pharmaceutical manufacturer with a broad domestic and international generic portfolio, including operations in the US, Australia, and emerging markets. Comparable as an Indian generics manufacturer with international regulatory approvals and contract manufacturing capabilities.
• Ipca Laboratories: Indian pharmaceutical manufacturer with API and finished dosage form capabilities and overseas registrations. Comparable as an Indian pharma manufacturer producing generic tablets, oral formulations, and hormonal products for international markets.
• Aurobindo Pharma: Indian generic pharmaceutical manufacturer with extensive export operations including to Africa, Latin America, and Asia. Comparable as a vertically integrated Indian generics manufacturer with WHO GMP plants and a broad generic portfolio spanning many of the same therapeutic categories Unicure serves.
• Emcure Pharmaceuticals: Indian pharmaceutical company with manufacturing facilities, R&D, and a presence across global markets including emerging economies. Comparable as an Indian-headquartered pharma manufacturer with contract manufacturing services, generic portfolio, and international regulatory certifications.
• Cipla: One of India's largest generic pharmaceutical manufacturers with a significant emerging-markets footprint across Africa, Latin America, and Asia. Comparable as an Indian-headquartered generic pharma exporter serving similar therapeutic categories (anti-malarial, respiratory, cardiovascular) under WHO GMP, though at vastly greater scale and brand recognition.

Direct peers

• Ajanta Pharma: Indian pharmaceutical company with a strong emerging-markets footprint in Africa, Asia, and Latin America. Comparable as a mid-sized Indian pharma exporter serving similar geographies, with a generic product portfolio and overseas regulatory registrations as a key growth driver.
• Strides Pharma Science: Indian pharmaceutical company with a focused emerging-markets strategy (particularly Africa under the 'Strides Pharma' brand) plus contract manufacturing. Highly comparable given its explicit emerging-market orientation, WHO GMP manufacturing base, and combined branded-generic plus B2B model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Unicure-Remedies-100054423132597
• LinkedInlinkedin.com/company/unicure-remedies

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unicure Remedies